



SOSEI ANNOUNCES EXPIRATION OF STOCK ACQUISITION RIGHTS

Tokyo, Japan – 25 December 2009: Sosei Group Corporation (“Sosei”, TSE Mothers Index: 4565), a biopharmaceutical company, today announces that it has resolved at the Board of Directors meeting held today to allow expiration of all of the Stock Acquisition Rights (30,600 shares of common stock of the Company) allotted to Nomura Securities Co., Ltd. (“Nomura”) on 7 December 2007.

Enquiries:

Sosei Group Corporation	
Tokyo office: Hidetoshi TORAMI Director of Finance +81-(0)3-5210-3399 htorami@sosei.com	London office: Yumi YAMAMOTO Manager, Finance and IR Europe +44-(0)20-7691-2081 yyamamoto@sosei.com

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan. For further information about Sosei, please visit www.sosei.com.